Benefits from hormonal therapy in patients with hormon-sensitive breast cancers are widely and well known. A great challenge for clinicians is represented by the possibility to use citoreductive primary hormonal therapy in patients with locally advanced breast carcinoma. Five-year treatment with tamoxifen has been for long time the gold standard in adjuvant settings. In post-menopausal women affected by breast cancer larger than 3 cm and expressing estrogen receptors (ER+), clinical trials have shown that few months treatment with aromatase inhibitors can downsizing tumors. This citoreduction is greater than the one obtained with tamoxifen and it makes conservative surgery possible in most part of cases.

[Aromatase inhibitors in advanced breast cancer] / Spinelli, GIAN PAOLO; Tomao, Federica; Miele, Evelina; G., Pasciuti; M., Russillo; Tomao, Silverio. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - STAMPA. - 99:1(2008), pp. 34-36.

[Aromatase inhibitors in advanced breast cancer].

SPINELLI, GIAN PAOLO;TOMAO, FEDERICA;MIELE, EVELINA;TOMAO, SILVERIO
2008

Abstract

Benefits from hormonal therapy in patients with hormon-sensitive breast cancers are widely and well known. A great challenge for clinicians is represented by the possibility to use citoreductive primary hormonal therapy in patients with locally advanced breast carcinoma. Five-year treatment with tamoxifen has been for long time the gold standard in adjuvant settings. In post-menopausal women affected by breast cancer larger than 3 cm and expressing estrogen receptors (ER+), clinical trials have shown that few months treatment with aromatase inhibitors can downsizing tumors. This citoreduction is greater than the one obtained with tamoxifen and it makes conservative surgery possible in most part of cases.
aromatase; breast cancer; inhibitors
01 Pubblicazione su rivista::01a Articolo in rivista
[Aromatase inhibitors in advanced breast cancer] / Spinelli, GIAN PAOLO; Tomao, Federica; Miele, Evelina; G., Pasciuti; M., Russillo; Tomao, Silverio. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - STAMPA. - 99:1(2008), pp. 34-36.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/357690
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? ND
social impact